Clinical Trials Browser

Withdrawn × Fallopian Tube Neoplasms × Clear all

NCT06545617 2026-01-07

A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

Phase 1/2 Withdrawn

Fallopian Tube Neoplasms

NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Phase 1/2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02756130 2025-05-13

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

Phase 1/2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04889495 2025-03-19

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

BreastGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Kidney Neoplasms, Colorectal Neoplasms

NCT01445275 2024-08-21

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

BreastGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

NCT03735589 2023-11-22

Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04510584 2023-06-06

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms

NCT00499291 2023-05-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Phase NA Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Teratoma, Testicular, Teratoma, Ovarian, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Teratoma, Testicular Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT05368506 2023-05-06

ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

Phase EARLY_PHASE1 Withdrawn

BreastGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04368130 2022-10-14

SIGNAL

Phase NA Withdrawn

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT03905902 2021-12-23

VITALIA

Phase 3 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03607955 2021-09-29

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Phase 1 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT03902379 2021-04-19

Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer

Phase NA Withdrawn

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms

NCT02487849 2020-03-04

HIPEC

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00693342 2020-02-24

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Phase 3 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01766622 2019-12-04

18F-CP18 Imaging Studies for Cancer Treatment With Birinapant

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02948101 2019-03-12

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02050009 2019-02-20

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02530606 2018-11-28

Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer

Phase NA Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00005645 2018-09-18

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Phase 2 Withdrawn

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pleural Effusion, Malignant

NCT02872519 2018-06-06

PET Imaging of Ovarian Carcinoma With 18F-FSPG

Phase EARLY_PHASE1 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02833506 2018-05-01

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00551265 2017-07-14

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Phase NA Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627430 2016-07-26

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT00634894 2016-04-20

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02470559 2016-02-17

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Phase 1 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01492920 2014-12-31

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Phase 3 Withdrawn

Brenner Tumor, Fallopian Tube Neoplasms, Fatigue, Ovarian Neoplasms, Pain, Neurotoxicity Syndromes

NCT01228942 2014-06-06

A Prospective Trial of COXEN Chemotherapy Prediction

Phase NA Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01131039 2013-12-20

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01982487 2013-12-18

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Phase 1/2 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00369954 2013-06-10

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01661868 2012-08-21

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms